Table 3.
Proportion of patients with virological cure (negative nasopharyngeal PCR) by day, in COVID-19 patients treated with hydroxychloroquine only, in COVID-19 patients treated with hydroxychloroquine and azithromycin combination, and in COVID-19 control patients.
| Day3 post inclusion |
Day4 post inclusion |
Day5 post inclusion |
Day6 post inclusion |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of negative patients/total number of patients | % | p-value | Number of negative patients/total number of patients | % | p-value | Number of negative patients/total number of patients | % | p-value | Number of negative patients/total number of patients | % | p-value | |
| Control patients | 1/16 | 6.3 | 0.002 | 4/16 | 25.0 | 0.05 | 3/16 | 18.8 | 0.002 | 2/16 | 12.5 | <0.001 |
| Hydroxychloroquine treatment only | 5/14 | 35.7 | 7/14 | 50.0 | 7/14 | 50.0 | 8/14 | 57.1 | ||||
| Hydroxychloroquine and azithromycin combined treatment | 5/6 | 83.3 | 5/6 | 83.3 | 6/6 | 100 | 6/6 | 100 | ||||